Kidney transplantation (KT) is the treatment of choice for chronic kidney disease patients, but there is a continued loss of grafts in the long-term (50% at 10 years) due to either patient death or chronic allograft dysfunction. Metabolic syndrome (MS) is very prevalent after KT (30–40%) and its components contribute to the appearance of nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease (NAFLD/MAFLD) and nonalcoholic steatohepatitis (NASH), which represent the hepatic component of MS. Furthermore, about 20–40% of KT recipients present early graft inflammation, including subclinical inflammation. Thus, the relationship between NAFLD-MAFLD/NASH and graft inflammation may be bidirectional, though no definite link between NAFLD-NASH and graft inflammation is currently known. Additionally, MS-related risk factors are associated with modern immunosuppressants and a negative synergistic effect on graft and patient survival seems plausible. Indeed, proinflammatory cytokines and adipokines released by adipose tissue can generate a low-grade inflammatory state and endothelial dysfunction, both involved in the appearance of CVD, and these disorders are associated with worsening liver lesions and subclinical and clinical atheromatosis. In this review, we discuss the recent clinical evidence regarding the prevalence and risk factors of MS and NAFLD/MAFLD following KT. Additionally, we propose the potential linking mechanism between NAFLD/MAFLD-NASH and post-KT graft inflammation, as well as alternative therapies for NAFLD after KT. Prevention of long-term life-threatening complications in this particular population rests upon better understanding and management of these severe clinical complications.

1.
Hariharan
S
,
Israni
AK
,
Danovitch
G
.
Long-term survival after kidney transplantation
.
N Engl J Med
.
2021
;
385
(
8
):
729
43
.
2.
Younossi
Z
,
Tacke
F
,
Arrese
M
,
Chander Sharma
B
,
Mostafa
I
,
Bugianesi
E
, et al
.
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
.
Hepatology
.
2019
;
69
(
6
):
2672
82
.
3.
Eslam
M
,
Newsome
PN
,
Sarin
SK
,
Anstee
QM
,
Targher
G
,
Romero-Gomez
M
, et al
.
A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement
.
J Hepatol
.
2020
;
73
(
1
):
202
9
.
4.
Eslam
M
,
Sanyal
AJ
,
George
J
,
International Consensus Panel
.
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
.
Gastroenterology
.
2020
;
158
(
7
):
1999
2014 e1
.
5.
Kokkorakis
M
,
Muzurović
E
,
Volčanšek
Š
,
Chakhtoura
M
,
Hill
MA
,
Mikhailidis
DP
, et al
.
Steatotic liver disease: pathophysiology and emerging pharmacotherapies
.
Pharmacol Rev
.
2024
;
76
(
3
):
454
99
.
6.
Younossi
ZM
,
Paik
JM
,
Stepanova
M
,
Ong
J
,
Alqahtani
S
,
Henry
L
.
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
.
J Hepatol
.
2024
;
80
(
5
):
694
701
.
7.
Lee
YH
,
Song
SH
,
Song
SH
,
Shin
HS
,
Yang
J
,
Kim
MS
, et al
.
Clinical implications of changes in metabolic syndrome status after kidney transplantation: a nationwide prospective cohort study
.
Nephrol Dial Transpl
.
2023
;
38
(
12
):
2743
53
.
8.
Prasad
GV
,
Huang
M
,
Silver
SA
,
Al-Lawati
AI
,
Rapi
L
,
Nash
MM
, et al
.
Metabolic syndrome definitions and components in predicting major adverse cardiovascular events after kidney transplantation
.
Transpl Int
.
2015
;
28
(
1
):
79
88
.
9.
de Vries
AP
,
Bakker
SJ
,
van Son
WJ
,
van der Heide
JJ
,
Ploeg
RJ
,
The
HT
, et al
.
Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally
.
Am J Transpl
.
2004
;
4
(
10
):
1675
83
.
10.
Porrini
E
,
Delgado
P
,
Bigo
C
,
Alvarez
A
,
Cobo
M
,
Checa
MD
, et al
.
Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation
.
Am J Kidney Dis
.
2006
;
48
(
1
):
134
42
.
11.
Kumar
R
,
Priyadarshi
RN
,
Anand
U
.
Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations
.
J Clin Transl Hepatol
.
2020
;
8
(
1
):
76
86
.
12.
Byrne
CD
,
Targher
G
.
NAFLD: a multisystem disease
.
J Hepatol
.
2015
;
62
(
1 Suppl
):
S47
64
.
13.
Mehta
RB
,
Tandukar
S
,
Jorgensen
D
,
Randhawa
P
,
Sood
P
,
Puttarajappa
C
, et al
.
Early subclinical tubulitis and interstitial inflammation in kidney transplantation have adverse clinical implications
.
Kidney Int
.
2020
;
98
(
2
):
436
47
.
14.
Torres
IB
,
Reisaeter
AV
,
Moreso
F
,
Âsberg
A
,
Vidal
M
,
Garcia-Carro
C
, et al
.
Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants
.
Transpl Int
.
2017
;
30
(
11
):
1119
31
.
15.
Hernández
D
,
Alonso-Titos
J
,
Vázquez
T
,
León
M
,
Caballero
A
,
Cobo
MA
, et al
.
Clinical relevance of corticosteroid withdrawal on graft histological lesions in low-immunological-risk kidney transplant patients
.
J Clin Med
.
2021
;
10
(
9
):
2005
.
16.
Ortiz
F
,
Gelpi
R
,
Helanterä
I
,
Melilli
E
,
Honkanen
E
,
Bestard
O
, et al
.
Decreased kidney graft survival in low immunological risk patients showing inflammation in normal protocol biopsies
.
PLoS One
.
2016
;
11
(
8
):
e0159717
.
17.
Nankivell
BJ
,
Agrawal
N
,
Sharma
A
,
Taverniti
A
,
P’Ng
CH
,
Shingde
M
, et al
.
The clinical and pathological significance of borderline T cell-mediated rejection
.
Am J Transpl
.
2019
;
19
(
5
):
1452
63
.
18.
Moreso
F
,
Ibernon
M
,
Gomà
M
,
Carrera
M
,
Fulladosa
X
,
Hueso
M
, et al
.
Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss
.
Am J Transpl
.
2006
;
6
(
4
):
747
52
.
19.
Jardine
AG
,
Gaston
RS
,
Fellstrom
BC
,
Holdaas
H
.
Prevention of cardiovascular disease in adult recipients of kidney transplants
.
Lancet
.
2011
;
378
(
9800
):
1419
27
.
20.
Torres
A
,
Hernández
D
,
Moreso
F
,
Serón
D
,
Burgos
MD
,
Pallardó
LM
, et al
.
Randomized controlled trial assessing the impact of tacrolimus versus cyclosporine on the incidence of posttransplant diabetes mellitus
.
Kidney Int Rep
.
2018
;
3
(
6
):
1304
15
.
21.
Israni
AK
,
Snyder
JJ
,
Skeans
MA
,
Kasiske
BL
,
PORT Invest, Igators
.
Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant
.
Transpl Int
.
2012
;
25
(
7
):
748
57
.
22.
Mikolasevic
I
,
Lukenda
V
,
Racki
S
,
Milic
S
,
Sladoje-Martinovic
B
,
Orlic
L
.
Nonalcoholic fatty liver disease (NAFLD): a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients
.
Clin Interv Aging
.
2014
;
9
:
1295
303
.
23.
Mikolasevic
I
,
Orlic
L
,
Hrstic
I
,
Milic
S
.
Metabolic syndrome and non-alcoholic fatty liver disease after liver or kidney transplantation
.
Hepatol Res
.
2016
;
46
(
9
):
841
52
.
24.
Gore
JL
,
Pham
PT
,
Danovitch
GM
,
Wilkinson
AH
,
Rosenthal
JT
,
Lipshutz
GS
, et al
.
Obesity and outcome following renal transplantation
.
Am J Transpl
.
2006
;
6
(
2
):
357
63
.
25.
Midtvedt
K
,
Hjelmesaeth
J
,
Hartmann
A
,
Lund
K
,
Paulsen
D
,
Egeland
T
, et al
.
Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal
.
J Am Soc Nephrol
.
2004
;
15
(
12
):
3233
9
.
26.
Sui
W
,
Zou
H
,
Zou
G
,
Yan
Q
,
Chen
H
,
Che
W
, et al
.
Clinical study of the risk factors of insulin resistance and metabolic syndrome after kidney transplantation
.
Transpl Immunol
.
2008
;
20
(
1–2
):
95
8
.
27.
Li
X
,
Bhattacharya
D
,
Yuan
Y
,
Wei
C
,
Zhong
F
,
Ding
F
, et al
.
Chronic kidney disease in a murine model of non-alcoholic steatohepatitis (NASH)
.
Kidney Int
.
2024
;
105
(
3
):
540
61
.
28.
Dyson
J
,
Day
C
.
Treatment of non-alcoholic fatty liver disease
.
Dig Dis
.
2014
;
32
(
5
):
597
604
.
29.
Siddiqui
MS
,
Sterling
RK
.
Posttransplant metabolic syndrome
.
Int J Hepatol
.
2012
;
2012
:
891516
.
30.
Eckel
RH
,
Grundy
SM
,
Zimmet
PZ
.
The metabolic syndrome
.
Lancet
.
2005
;
365
(
9468
):
1415
28
.
31.
Mantovani
A
,
Scorletti
E
,
Mosca
A
,
Alisi
A
,
Byrne
CD
,
Targher
G
.
Complications, morbidity and mortality of nonalcoholic fatty liver disease
.
Metabolism
.
2020
;
111S
:
154170
.
32.
Lonardo
A
,
Mantovani
A
,
Targher
G
,
Baffy
G
.
Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications
.
Int J Mol Sci
.
2022
;
23
(
21
):
13320
.
33.
Oni
ET
,
Agatston
AS
,
Blaha
MJ
,
Fialkow
J
,
Cury
R
,
Sposito
A
, et al
.
A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care
.
Atherosclerosis
.
2013
;
230
(
2
):
258
67
.
34.
Grupper
A
,
Rabinowich
A
,
Ben Shabat
I
,
Tzadok
R
,
Schwartz
D
,
Schwartz
IF
, et al
.
Nonalcoholic fatty liver disease before kidney transplantation correlates with new onset diabetes and poor metabolic outcomes
.
Am J Nephrol
.
2022
;
53
(
8–9
):
636
45
.
35.
Mantovani
A
,
Lombardi
R
,
Cattazzo
F
,
Zusi
C
,
Cappelli
D
,
Dalbeni
A
.
MAFLD and CKD: an updated narrative review
.
Int J Mol Sci
.
2022
;
23
(
13
):
7007
.
36.
Targher
G
,
Byrne
CD
.
Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease
.
Nat Rev Nephrol
.
2017
;
13
(
5
):
297
310
.
37.
Bonora
E
,
Targher
G
.
Increased risk of cardiovascular disease and chronic kidney disease in NAFLD
.
Nat Rev Gastroenterol Hepatol
.
2012
;
9
(
7
):
372
81
.
38.
Prussick
RB
,
Miele
L
.
Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden
.
Br J Dermatol
.
2018
;
179
(
1
):
16
29
.
39.
Sun
G
,
Zhao
X
,
Li
M
,
Zhang
C
,
Jin
H
,
Li
C
, et al
.
CD4 derived double negative T cells prevent the development and progression of nonalcoholic steatohepatitis
.
Nat Commun
.
2021
;
12
(
1
):
650
.
40.
McLaughlin
T
,
Ackerman
SE
,
Shen
L
,
Engleman
E
.
Role of innate and adaptive immunity in obesity-associated metabolic disease
.
J Clin Invest
.
2017
;
127
(
1
):
5
13
.
41.
Gadd
VL
,
Patel
PJ
,
Jose
S
,
Horsfall
L
,
Powell
EE
,
Irvine
KM
.
Altered peripheral blood monocyte phenotype and function in chronic liver disease: implications for hepatic recruitment and systemic inflammation
.
PLoS One
.
2016
;
11
(
6
):
e0157771
.
42.
Caballero
A
,
Vazquez-Sanchez
T
,
Ruiz-Esteban
P
,
Leon
M
,
Alonso-Titos
J
,
Lopez
V
, et al
.
Decrease in CD14++CD16+ monocytes in low-immunological-risk kidney transplant patients with subclinical borderline inflammation
.
J Clin Med
.
2021
;
10
(
21
):
5051
.
43.
Van Herck
MA
,
Vonghia
L
,
Kwanten
WJ
,
Vanwolleghem
T
,
Ebo
DG
,
Michielsen
PP
, et al
.
Adoptive cell transfer of regulatory T cells exacerbates hepatic steatosis in high-fat high-fructose diet-fed mice
.
Front Immunol
.
2020
;
11
:
1711
.
44.
Puengel
T
,
Liu
H
,
Guillot
A
,
Heymann
F
,
Tacke
F
,
Peiseler
M
.
Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
.
Int J Mol Sci
.
2022
;
23
(
5
):
2668
.
45.
Cariello
M
,
Piccinin
E
,
Moschetta
A
.
Transcriptional regulation of metabolic pathways via lipid-sensing nuclear receptors PPARs, FXR, and LXR in NASH
.
Cell Mol Gastroenterol Hepatol
.
2021
;
11
(
5
):
1519
39
.
46.
Sun
Y
,
Demagny
H
,
Schoonjans
K
.
Emerging functions of the nuclear receptor LRH-1 in liver physiology and pathology
.
Biochim Biophys Acta Mol Basis Dis
.
2021
;
1867
(
8
):
166145
.
47.
Tanaka
N
,
Aoyama
T
,
Kimura
S
,
Gonzalez
FJ
.
Targeting nuclear receptors for the treatment of fatty liver disease
.
Pharmacol Ther
.
2017
;
179
:
142
57
.
48.
Xiao
Y
,
Kim
M
,
Lazar
MA
.
Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease
.
Mol Metab
.
2021
;
50
:
101119
.
49.
Cave
MC
,
Clair
HB
,
Hardesty
JE
,
Falkner
KC
,
Feng
W
,
Clark
BJ
, et al
.
Nuclear receptors and nonalcoholic fatty liver disease
.
Biochim Biophys Acta
.
2016
;
1859
(
9
):
1083
99
.
50.
Lee
YJ
,
Ko
EH
,
Kim
JE
,
Kim
E
,
Lee
H
,
Choi
H
, et al
.
Nuclear receptor PPARγ-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis
.
Proc Natl Acad Sci U S A
.
2012
;
109
(
34
):
13656
61
.
51.
Santos-Laso
A
,
Gutiérrez-Larrañaga
M
,
Alonso-Peña
M
,
Medina
JM
,
Iruzubieta
P
,
Arias-Loste
MT
, et al
.
Pathophysiological mechanisms in non-alcoholic fatty liver disease: from drivers to targets
.
Biomedicines
.
2021
;
10
(
1
):
46
.
52.
Khiatah
B
,
Nasrollah
L
,
Covington
S
,
Carlson
D
.
Nonalcoholic fatty liver disease as a risk factor for cytomegalovirus hepatitis in an immunocompetent patient: a case report
.
World J Clin Cases
.
2021
;
9
(
6
):
1455
60
.
53.
Salvadori
M
,
Tsalouchos
A
.
Microbiota, renal disease and renal transplantation
.
World J Transpl
.
2021
;
11
(
3
):
16
36
.
54.
Lee
JR
,
Muthukumar
T
,
Dadhania
D
,
Toussaint
NC
,
Ling
L
,
Pamer
E
, et al
.
Gut microbial community structure and complications after kidney transplantation: a pilot study
.
Transplantation
.
2014
;
98
(
7
):
697
705
.
55.
Lei
YM
,
Chen
L
,
Wang
Y
,
Stefka
AT
,
Molinero
LL
,
Theriault
B
, et al
.
The composition of the microbiota modulates allograft rejection
.
J Clin Invest
.
2016
;
126
(
7
):
2736
44
.
56.
Izquierdo
MC
,
Perez-Gomez
MV
,
Sanchez-Niño
MD
,
Sanz
AB
,
Ruiz-Andres
O
,
Poveda
J
, et al
.
Klotho, phosphate and inflammation/ageing in chronic kidney disease
.
Nephrol Dial Transpl
.
2012
;
27
(
Suppl 4
):
iv6
10
.
57.
Kulshrestha
S
,
Ojo
AO
,
Luan
FL
.
Metabolic syndrome, vitamin D deficiency and hypoadiponectinemia among nondiabetic patients early after kidney transplantation
.
Am J Nephrol
.
2013
;
37
(
5
):
399
404
.
58.
Targher
G
,
Bertolini
L
,
Scala
L
,
Cigolini
M
,
Zenari
L
,
Falezza
G
, et al
.
Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease
.
Nutr Metab Cardiovasc Dis
.
2007
;
17
(
7
):
517
24
.
59.
Manco
M
,
Ciampalini
P
,
Nobili
V
.
Low levels of 25-hydroxyvitamin D(3) in children with biopsy-proven nonalcoholic fatty liver disease
.
Hepatology
.
2010
;
51
(
6
):
2229
30
.
60.
Aranow
C
.
Vitamin D and the immune system
.
J Investig Med
.
2011
;
59
(
6
):
881
6
.
61.
Hutchison
AL
,
Tavaglione
F
,
Romeo
S
,
Charlton
M
.
Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance
.
J Hepatol
.
2023
;
79
(
6
):
1524
41
.
62.
Papalia
T
,
Greco
R
,
Lofaro
D
,
Mollica
A
,
Bonofiglio
R
.
Thyroid status and kidney transplantation outcomes
.
Transpl Proc
.
2011
;
43
(
4
):
1042
4
.
63.
Byrne
CD
,
Patel
J
,
Scorletti
E
,
Targher
G
.
Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults
.
Bmj
.
2018
;
362
:
k2734
.
64.
Rinella
ME
,
Neuschwander-Tetri
BA
,
Siddiqui
MS
,
Abdelmalek
MF
,
Caldwell
S
,
Barb
D
, et al
.
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
.
Hepatology
.
2023
;
77
(
5
):
1797
835
.
65.
Luo
HY
,
Mu
WJ
,
Chen
M
,
Zhu
JY
,
Li
Y
,
Li
S
, et al
.
Hepatic Klf10-Fh1 axis promotes exercise-mediated amelioration of NASH in mice
.
Metabolism
.
2024
;
155
:
155916
.
66.
Wang
H
,
Ma
Q
,
Chen
Y
,
Luo
L
,
Ye
J
,
Zhong
B
.
Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: a network meta-analysis of randomized controlled trials
.
Obes Rev
.
2024
;
25
(
6
):
e13727
.
67.
Febles
RM
,
Miranda
DM
,
Perera
CCC
,
Martín
LD
,
Rodríguez-Rodríguez
AE
,
González Martín
AR
, et al
.
Therapeutic exercise on metabolic and renal outcomes in patients with chronic kidney disease: a narrative review
.
Nephron
.
2024
;
148
(
2
):
85
94
.
68.
Mikolasevic
I
,
Filipec-Kanizaj
T
,
Mijic
M
,
Jakopcic
I
,
Milic
S
,
Hrstic
I
, et al
.
Nonalcoholic fatty liver disease and liver transplantation: where do we stand
.
World J Gastroenterol
.
2018
;
24
(
14
):
1491
506
.
69.
Kong
M
,
Xu
M
,
Zhou
Y
,
Geng
N
,
Lin
N
,
Song
W
, et al
.
Assessing visceral obesity and abdominal adipose tissue distribution in healthy populations based on computed tomography: a large multicenter cross-sectional study
.
Front Nutr
.
2022
;
9
:
871697
.
70.
Leite
NC
,
Viegas
BB
,
Villela-Nogueira
CA
,
Carlos
FO
,
Cardoso
CRL
,
Salles
GF
.
Efficacy of diacerein in reducing liver steatosis and fibrosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized, placebo-controlled trial
.
Diabetes Obes Metab
.
2019
;
21
(
5
):
1266
70
.
71.
Kuchay
MS
,
Krishan
S
,
Mishra
SK
,
Farooqui
KJ
,
Singh
MK
,
Wasir
JS
, et al
.
Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)
.
Diabetes Care
.
2018
;
41
(
8
):
1801
8
.
72.
Knop
FK
,
Bronden
A
,
Vilsboll
T
.
Exenatide: pharmacokinetics, clinical use, and future directions
.
Expert Opin Pharmacother
.
2017
;
18
(
6
):
555
71
.
73.
Deng
M
,
Wen
Y
,
Yan
J
,
Fan
Y
,
Wang
Z
,
Zhang
R
, et al
.
Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials
.
BMC Med
.
2023
;
21
(
1
):
447
.
74.
Patel Chavez
C
,
Cusi
K
,
Kadiyala
S
.
The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD
.
J Clin Endocrinol Metab
.
2022
;
107
(
1
):
29
38
.
75.
Huang
KH
,
Lee
CH
,
Cheng
YD
,
Gau
SY
,
Tsai
TH
,
Chung
NJ
, et al
.
Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: a real-world cohort study
.
Front Endocrinol
.
2022
;
13
:
1027484
.
76.
Lian
J
,
Wang
H
,
Cui
R
,
Zhang
C
,
Fu
J
.
Status of analgesic drugs and quality of life results for diabetic peripheral neuropathy in China
.
Front Endocrinol
.
2021
;
12
:
813210
.
77.
Lian
J
,
Fu
J
.
Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis
.
Front Endocrinol
.
2021
;
12
:
615409
.
78.
Wei
Q
,
Xu
X
,
Guo
L
,
Li
J
,
Li
L
.
Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials
.
Front Endocrinol
.
2021
;
12
:
635556
.
79.
Zhu
Y
,
Xu
J
,
Zhang
D
,
Mu
X
,
Shi
Y
,
Chen
S
, et al
.
Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis
.
Front Endocrinol
.
2021
;
12
:
769069
.
80.
Wang
Y
,
Yi
H
,
Sun
W
,
Yu
H
,
Tao
W
,
Yu
X
, et al
.
Comparative efficacy of drug interventions on NAFLD over 24 Weeks: a traditional and network meta-analysis of randomized controlled trials
.
Drugs
.
2024
;
84
(
4
):
425
39
.
81.
Xie
W
,
Hong
Z
,
Li
B
,
Huang
B
,
Dong
S
,
Cai
Y
, et al
.
Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: a systematic review and meta-analysis of randomized control trials
.
J Diabetes Complications
.
2024
;
38
(
6
):
108743
.
82.
He
J
,
Hu
K
,
Wang
B
,
Wang
H
.
Effect of dietary and physical activity behavioral interventions on reducing postpartum weight retention among women with recent gestational diabetes: a systematic review and meta-analysis of randomized controlled trials
.
Obes Rev
.
2024
;
25
(
4
):
1
771
.
83.
Dongiovanni
P
,
Petta
S
,
Mannisto
V
,
Mancina
RM
,
Pipitone
R
,
Karja
V
, et al
.
Statin use and non-alcoholic steatohepatitis in at risk individuals
.
J Hepatol
.
2015
;
63
(
3
):
705
12
.
84.
Harrison
SA
,
Bedossa
P
,
Guy
CD
,
Schattenberg
JM
,
Loomba
R
,
Taub
R
, et al
.
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
.
N Engl J Med
.
2024
;
390
(
6
):
497
509
.
85.
Keam
SJ
.
Resmetirom: first approval
.
Drugs
.
2024
;
84
(
6
):
729
35
.
You do not currently have access to this content.